| Paris | |
| 0 | |
| Develops cutting-edge immune-based treatments for high unmet medical needs through our versatile and targeted vaccine platform. | |
| VAC-3S is an immunotherapy, currently in phase 2 clinical trial, that will change the paradigm of HIV therapy allowing patients to undergo functional cure (i.e. stop antiretrovirals therapy). | |
| CROUZET Joel | |
| www.innavirvax.fr | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 51 fois.